Eunice Tzeng

Principal Medical Science Director
Genentech, Inc.
South San Francisco, California, United States

Presentation(s):

• PB0216 - Hemoglobin improvement among patients with hemophilia A treated with emicizumab prophylaxis: post hoc analysis of the HAVEN 1, 3, 4 and STASEY trials

  Sunday, June 23, 2024
  13:45 – 14:45 ICT